Pfizer remains our top drug stock

Article Excerpt

We now see several promising opportunities emerging in the pharmaceutical drug industry, and we will probably recommend more drug stocks in the next few years. For now, we feel Pfizer offers our readers the best combination of growth and income in a pharma stock. Since we first recommended it as a buy in 2011, the company has rewarded our readers with a solid 80% gain—and a near doubling of its dividend. Pfizer is one of several drugmakers that are racing to develop a COVID-19 vaccine. Even if its vaccine fails, investors should continue to benefit as the company works on widening its range of other promising drugs. Moreover, Pfizer’s plan to cut its exposure to less-profitable generic drugs should boost your long-term returns. PFIZER INC. $36 is a buy. The company (New York symbol PFE; Income Portfolio, Manufacturing & Industry sector; Shares outstanding: 5.6 billion; Market cap: $201.6 billion; Price-to-sales ratio: 4.1; Dividend yield: 4.2%; TSINetwork Rating: Above Average; www.pfizer.com) began operating in 1849 and…